CH
CHRS.US Coherus BioSciences Inc
- Market cap
- USD 81.2M
- P/E
- -
- P/B
- 3.28x
- ROE
- -517.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CHRS.US undervalued?
Graham numberThe Graham number of Coherus BioSciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Coherus BioSciences Inc fundamental analysis
No fundamental analysis for Coherus BioSciences Inc yet.
Coherus BioSciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develop…
Full company profileCoherus BioSciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Coherus BioSciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 190M | 1.56M | 1.56M | 356M | 476M | 327M | 211M | 257M | 267M | 42.2M | 54.5M |
| Gross Profit | -64.3M | -159M | -1.68M | 339M | 438M | 269M | 141M | 98.3M | 149M | 24.4M | 37.1M |
| Operating Income | -116M | -232M | -204M | 108M | 156M | -264M | -257M | -203M | -112M | -180M | -136M |
| EBITDA | -117M | -225M | -204M | 111M | 160M | -261M | -256M | -194M | 60.9M | -170M | -132M |
| Net Income | -127M | -238M | -209M | 89.8M | 132M | -287M | -292M | -238M | 28.5M | -170M | -131M |
| EPS | -3.04 | -4.48 | -3.22 | 1.23 | 1.58 | -3.81 | -3.76 | -2.53 | 0.25 | -1.41 | -0.84 |
| Balance Sheet | |||||||||||
| Total Assets | 178M | 163M | 99.5M | 409M | 842M | 679M | 481M | 630M | 449M | 258M | 171M |
| Total Liabilities | 159M | 132M | 138M | 304M | 561M | 582M | 618M | 823M | 581M | 197M | 146M |
| Shareholders' Equity | 19.4M | 30.5M | -38.6M | 105M | 281M | 97.7M | -137M | -193M | -132M | 61.0M | 25.2M |
| Cash & Short-term Investments | 125M | 127M | 72.4M | 178M | 541M | 417M | 192M | 118M | 126M | 172M | 83.6M |
| Total Debt | 101M | 102M | 103M | 181M | 417M | 419M | 480M | 481M | 270M | 40.3M | 69.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -253M | -200M | -159M | 28.4M | 154M | -37.4M | -241M | -175M | -20.4M | -139M | -283M |
| Capital Expenditure | 6.52M | 4.57M | 789K | 12.9M | 7.23M | 1.29M | 2.04M | 286K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -259M | -205M | -160M | 15.5M | 147M | -38.7M | -243M | -175M | -20.4M | -139M | -283M |
| Ratios | |||||||||||
| ROE | -657.9% | -780.0% | - | 85.4% | 47.1% | -293.8% | - | - | - | -279.1% | -517.0% |
| ROA | -71.3% | -146.5% | -210.5% | 22.0% | 15.7% | -42.3% | -60.7% | -37.8% | 6.4% | -65.9% | -76.3% |
| Net Profit Margin | -67.0% | -15,306.6% | -13,453.7% | 25.2% | 27.8% | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% | -239.4% |
| Debt to Equity | 5.23x | 3.34x | - | 1.72x | 1.48x | 4.29x | - | - | - | 0.66x | 2.75x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Coherus BioSciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 3.74M | 0.05 | - |
| 2021 | USD 1.75M | 0.02 | - |
| 2020 | USD 20.3M | 0.24 | 15.4% |
| 2019 | USD 72.1M | 0.99 | 80.3% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Coherus BioSciences Inc
- Insiders 19.70%
- Institutions 35.83%
- Public & others 44.47%
- Shares outstanding 155M
- Free float 148M
Top funds holding CHRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 6.45M | 4.18% | 0.00% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.95M | 2.56% | 0.00% | Sep 2026 |
| HBM Healthcare Investments AG Ord | 3.71M | 2.40% | 0.00% | Sep 2026 |
| C WorldWide Healthcare Select 1A | 1.93M | 1.25% | 0.00% | Sep 2026 |
| Nomura Healthcare Fund Class I | 1.80M | 1.17% | +100.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 1.48M | 0.96% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.33M | 0.86% | -6.81% | Aug 2026 |
| BlackRock Advantage Small Cap Core Instl | 928K | 0.60% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 884K | 0.57% | -0.19% | Oct 2026 |
| iShares Micro-Cap ETF | 757K | 0.49% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 707K | 0.46% | -5.60% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 699K | 0.45% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 630K | 0.41% | -17.38% | Sep 2026 |
| Schwab Small Cap Index | 318K | 0.21% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 271K | 0.18% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 237K | 0.15% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 232K | 0.15% | -15.49% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 205K | 0.13% | 0.00% | Oct 2026 |
| Bridgeway Ultra-Small Company | 191K | 0.12% | -34.36% | Jun 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 175K | 0.11% | 0.00% | Oct 2026 |
Top institutions holding CHRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 13.1M | 8.45% | +6.18% | Jun 2026 |
| BlackRock Inc | 12.0M | 7.77% | +15.81% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.95M | 3.85% | +9.11% | Jun 2026 |
| Geode Capital Management, LLC | 3.69M | 2.39% | +18.07% | Jun 2026 |
| Samsara BioCapital, LLC | 3.43M | 2.22% | 0.00% | Jun 2026 |
| Kohlberg Kravis Roberts & Co LP | 3.04M | 1.97% | 0.00% | Jun 2026 |
| State Street Corp | 2.38M | 1.54% | +2.43% | Jun 2026 |
| Two Sigma Investments LLC | 2.26M | 1.46% | -1.85% | Jun 2026 |
| CM Management, LLC | 2.10M | 1.36% | 0.00% | Jun 2026 |
| CAM Group Holding A/S | 1.93M | 1.25% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 1.73M | 1.12% | -22.97% | Jun 2026 |
| Hudson Bay Capital Management LP | 1.69M | 1.10% | -0.70% | Jun 2026 |
| AQR Capital Management LLC | 1.33M | 0.86% | +10.29% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.23M | 0.79% | +6.24% | Jun 2026 |
| Panagora Asset Management Inc | 1.14M | 0.74% | -22.06% | Jun 2026 |
| Northern Trust Corp | 1.13M | 0.73% | +23.60% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.02M | 0.66% | +6.96% | Jun 2026 |
| Delaware Management Holdings Inc | 900K | 0.58% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 883K | 0.57% | +46.14% | Jun 2026 |
| UBS Group AG | 760K | 0.49% | +38.95% | Jun 2026 |
Coherus BioSciences Inc company profile
- Company name
- Coherus BioSciences Inc
- Ticker
- CHRS.US
- Exchange
- USA Stocks
- Listed since
- Nov 6, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Fiscal year end
- December
- Address
- 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065
- Phone
- 650 649 3530
- Website
- coherus.com
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Coherus BioSciences Inc management
10- Mr. Dennis M. LanfearChairman, President & CEO · born 1955
- Mr. Bryan J. McMichaelChief Financial Officer · born 1979
- Ms. Carrie GrahamVice President of Investor Relations & Advocacy
- Mr. Andy RittenbergChief Legal Officer
- Ms. Rebecca SunshineChief Human Resources Officer · born 1963
- Mr. Michael ChenSenior Vice President of Commercial Analytics & Trade
- Dr. Theresa M. Lavallee Ph.D.Chief Development Officer & Chairman of Scientific Advisory Board · born 1966
- Dr. Rosh Dias M.D., MRCPChief Medical Officer · born 1968
- Mr. Arvind SoodChief Strategy & Corporate Affairs Officer
- Mr. Sameer GoregaokerChief Commercial Officer